Recombinant Mouse IL-36 beta/IL-1F8 (aa 31-183) Protein

Recombinant Mouse IL-36 beta /IL-1F8 (aa 31‑183) (Catalog # 7060-ML) induces IL-6 secretion in the NIH‑3T3 mouse embryonic fibroblast cell line. The ED50 for this effect is 1-6 ng/mL.

1 µg/lane of Recombinant Mouse IL‑36 beta /IL‑1F8 (aa 31-183) was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 16 kDa.

• Reactivity: Mu
• Applications: Bioactivity

Recombinant Mouse IL-36 beta/IL-1F8 (aa 31-183) Protein Summary

• Details of Functionality: Measured by its ability to induce IL-6 secretion by NIH‑3T3 mouse embryonic fibroblast cells. Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677. The ED₅₀ for this effect is 1-6 ng/mL.
• Source: E. coli-derived mouse IL-36 beta/IL-1F8 protein
  Ser31-Lys183
• Accession #: Q9D6Z6
• N-terminal Sequence: Ser31
• Protein/Peptide Type: Recombinant Proteins
• Gene: Il1f8
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 17.4 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 16 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in MES, NaCl, TCEP, EDTA, CHAPS and PEG 8000 with BSA as a carrier protein.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in 10 mM Tris-HCl, pH 8.0.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse IL-36 beta/IL-1F8 (aa 31-183) Protein

• family of interleukin 1-eta
• FIL1 eta
• FIL1
• FIL1-(ETA)
• FIL1H
• FILI-(ETA)
• IL-1 eta
• IL1-ETA
• IL1F8 (Canonical product IL-1F8a)
• IL-1F8 (FIL1-eta)
• IL1F8
• IL-1F8
• IL1H2
• IL-1H2
• IL36 beta
• IL-36 beta
• IL36B
• interleukin 1 family, member 8 (eta)
• interleukin 1, eta
• Interleukin 36, Beta
• Interleukin-1 eta
• interleukin-1 family member 8
• Interleukin-1 homolog 2
• Interleukin-1 Superfamily e
• Interleukin-36 Beta

Background

Mouse interleukin‑36 beta [IL-36 beta ; previously IL‑1F8, FIL‑1 eta  (eta) and IL‑1H2] is a member of the IL‑1 family of proteins that includes IL‑1 beta , IL‑1 alpha , IL‑1ra, IL‑18, IL‑36Ra/IL‑1F5, IL‑36 alpha /IL‑1F6, IL‑37/IL‑1F7, IL‑36 gamma /IL‑1F9 and IL‑1F10 (1 ‑ 6). All family members show a 12 beta ‑stranded beta ‑trefoil configuration, share up to 50% amino acid (aa) sequence identity, and are believed to have arisen from a common ancestral gene (3, 4). Although two alternatively spliced transcript variants for human IL‑36 beta /IL‑1F8 have been described, to date, only one mouse IL‑36 beta /IL‑1F8 isoform is known (3). Mouse IL‑36 beta /IL‑1F8 is synthesized as a 183 amino acid (aa) protein that contains no signal sequence, no prosegment and no potential N‑linked glycosylation site(s) (1, 2). Mouse IL‑36 beta /IL‑1F8 shares 61% and 74% aa identity with human IL‑36 beta isoform 2 and rat IL‑36 beta , respectively. IL‑36 beta is agonistic, stimulating release of inflammatory mediators such as IL‑6 and IL‑8, and cytotoxic peptides such as beta-defensins 2 and 3 that aid in defense against microbial pathogens (7 ‑ 10). The receptor for IL-36 proteins is IL‑1 Rrp2, with IL‑1 RAcP as a coreceptor (7, 9). Antagonism of IL‑36 proteins by IL‑36Ra, which also binds IL‑1 Rrp2, has been shown by some investigators (5, 6). Skin keratinocytes express highest levels of IL‑36 proteins and their receptors, followed by epithelia in the esophagus, trachea and bronchae (7 ‑ 9). IL‑36 beta expression is increased in psoriatic skin and may play a role in pathogenesis of psoriasis (7, 8). IL‑36 beta is also expressed in resting and activated monocytes and B cells, synovial fibroblasts, neurons and glia, and is detectable in plasma and body fluids (1, 7, 9, 11). IL‑36 beta , along with IL‑36 alpha and IL‑36 gamma , is up‑regulated by IL‑1 alpha and TNF‑ alpha in keratinocytes, and has been shown to activate NF‑ kappa B and MAPK signaling pathways in an IL‑1 Rrp2‑dependent manner (7 ‑ 9). Full‑length recombinant IL‑36 proteins appear less active than their endogenous counterparts, but trimming of the N‑termini enhances their activity (9, 12).

1. Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
2. Kumar, S. et al. (2000) J. Biol. Chem. 275:10308.
3. Nicklin, M.J.H. et al. (2002) Genomics 79:718.
4. Dunn, E. et al. (2001) Trends Immunol. 22:533.
5. Dinarello, C. et al. (2010) Nat. Immunol. 11:973.
6. Barksby, H.E. et al. (2007) Clin. Exp. Immunol. 149:217.
7. Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.
8. Johnston, A. et al. (2011) J. Immunol. 186:2613.
9. Magne, D. et al. (2005) Arthritis Res. Ther. 8:R80.
10. van Asseldonk, E.J.P. et al. (2010) Obesity 18:2234.
11. Wang, P. et al. (2005) Cytokine 29:245.
12. Blumberg, H. et al. (2010) J. Immunol. 185:4354.

Publications for IL-36 beta/IL-1F8 (7060-ML)(1)

Publication using 7060-ML

• Tortola L, Rosenwald E, Abel B, Blumberg H, Schafer M, Coyle A, Renauld J, Werner S, Kisielow J, Kopf M Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest, 2012-10-15;122(11):3965-76. 2012-10-15 [PMID: 23064362] (Bioassay, Mouse)

Bioinformatics

• Gene Symbol: Il1f8
• Uniprot:
  • Q9D6Z6()